Vestmark Advisory Solutions Inc. Has $2.86 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Vestmark Advisory Solutions Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 27,629 shares of the company’s stock after selling 1,788 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Novo Nordisk A/S were worth $2,858,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NVO. Jennison Associates LLC increased its holdings in shares of Novo Nordisk A/S by 100.3% during the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after acquiring an additional 11,727,507 shares in the last quarter. FMR LLC increased its stake in Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares in the last quarter. Morgan Stanley raised its holdings in Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after buying an additional 4,350,862 shares in the last quarter. Finally, Polen Capital Management LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $718,995,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on NVO. UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $0.97 during trading hours on Friday, hitting $123.05. 5,932,926 shares of the company’s stock traded hands, compared to its average volume of 3,905,318. The company has a fifty day simple moving average of $127.20 and a 200-day simple moving average of $112.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 2.06 and a beta of 0.43. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 92.21%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.